"There are so many unknowns commercially," said Scott Foraker, who heads Amgen's year-old biosimilars unit. "We don't know what the competitive environment will look like. We don't know what the pricing will be. And there still is regulatory uncertainty."
Date: Feb 09, 2012
Category: Health
Source: Google
Amgen And Watson Join Forces To Develop Generic Cancer Drugs
One of our built in advantages is to use the same quality of manufacturing, says Scott Foraker, the Amgen vice president in charge of biosimilars. You can trust the new products same way you trusted Amgen biologics over the past 30 years.
Date: Dec 19, 2011
Category: Health
Source: Google
Amgen, Watson to collaborate on cancer biosimilars
Scott Foraker, head of Amgen's biosimilar division, said the company was fully committed to the effort and expects to see Amgen/Watson biosimilar products on the market in "the second half of this decade."